Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization.

BioRxiv : the Preprint Server for Biology
Pengfei WangDavid D Ho


The Covid-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2, continues to rage. Prospects of ending this pandemic rest on the development of effective interventions. Single and combination monoclonal antibody (mAb) therapeutics have received emergency use authorization 1,2 , with more in the pipeline 3-6 . Furthermore, multiple vaccine constructs have shown promise 7 , including two with ~95% protective efficacy against Covid-19 8,9 . However, these interventions were directed toward the initial SARS-CoV-2 that emerged in 2019. Considerable viral evolution has occurred since, including variants with a D614G mutation 10 that have become dominant. Viruses with this mutation alone do not appear to be antigenically distinct, however 11 . Recent emergence of new SARS-CoV-2 variants B.1.1.7 in the UK 12 and B.1.351 in South Africa 13 is of concern because of their purported ease of transmission and extensive mutations in the spike protein. We now report that B.1.1.7 is refractory to neutralization by most mAbs to the N-terminal domain (NTD) of spike and relatively resistant to a number of mAbs to the receptor-binding domain (RBD). It is modestly more resistant to convalescent plasma (~3 fold) and vaccinee sera (~...Continue Reading


Feb 10, 2021·Nature·Dennis R Burton, Eric J Topol
Feb 18, 2021·JAMA : the Journal of the American Medical Association·Rochelle P WalenskyAnthony S Fauci
Mar 4, 2021·Nature Medicine·Constantinos K WibmerPenny L Moore
Mar 16, 2021·Journal of Ethnopharmacology·M. S. NairP J Weathers
Mar 6, 2021·Emerging Microbes & Infections·Kelvin Kai-Wang ToKwok-Yung Yuen
Apr 4, 2021·International Journal of Molecular Sciences·Fanny PojeroAnna Aiello
Mar 31, 2021·Travel Medicine and Infectious Disease·Ranjit SahAlfonso J Rodriguez-Morales
Apr 12, 2021·Expert Review of Molecular Diagnostics·Jianfu J WangJin V Wu
Apr 14, 2021·Expert Review of Vaccines·Lianlian BianZhenglun Liang
May 1, 2021·Vaccines·Gaetano DonofrioGabriele Missale
Apr 21, 2021·Nature Reviews. Immunology·Peter C TaylorRobert L Gottlieb
May 1, 2021·Viruses·Aeron C Hurt, Adam K Wheatley
Apr 19, 2021·The Journal of Infection·Gabriela Rodrigues Barbosa
Apr 7, 2021·JCI Insight·Jonathan L GolobAnna S Lok
May 12, 2021·Nature Communications·Irwin JungreisManolis Kellis
Apr 21, 2021·JMIR Public Health and Surveillance·Hashaam AkhtarYousef Saleh Khader
Jun 9, 2021·Scientific Reports·Luis Fernando Saraiva Macedo TimmersStefan Laufer

Related Concepts

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.